IMUX @ 23.49 up 36% > Immunic shares are trading higher after the company announced the results from its Phase 2 EMPhASIS trial of IMU-838 in patients with Relapsing-Remitting Multiple Sclerosis achieved all primary and key secondary endpoints.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.